New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere

References

• Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;149(4):778–789. doi: 10.1002/ijc.33588
   Web of Science ®Google Scholar
• Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics 2022. CA Cancer J Clin. 2022;73(1):17–48.
   Web of Science ®Google Scholar
• Crosbie E, Kitson SJ, McAlpine JN, et al. Endometrial cancer. Lancet. 2022;399(10333):1412–1428.
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. ACOG committee opinion No. 734: the role of transvaginal ultrasonography in evaluating the endometrium of women with postmenopausal bleeding. Obstet Gynecol. 2018;131(5):e124–e129. doi: 10.1097/AOG.0000000000002631
   PubMed Web of Science ®Google Scholar
• Riggs BL, Hartmann LC, Wood AJJ. Selective estrogen-receptor modulators — mechanisms of action and application to clinical practice. N Engl J Med. 2003;348(7):618–629. doi: 10.1056/NEJMra022219
   PubMed Web of Science ®Google Scholar
• Mourits MJ, De Vries EG, Willemse PH, et al. Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol. 2001;7(5 Pt 2):855–866. doi: 10.1097/00006250-200105000-00055
   Google Scholar
• Goldstein SR. The effect of SERMs on the endometrium. Ann N Y Acad Sci. 2001;949(1):237–242. doi: 10.1111/j.1749-6632.2001.tb04027.x
   PubMed Web of Science ®Google Scholar
• Committee on Gynecologic Practice. ACOG committee opinion No. 232: tamoxifen and endometrial cancer. Obstet Gynecol. 2000;95(4):1–3.
   PubMedGoogle Scholar
• Gasparri ML, Bellaminutti S, Farooqi AA, et al. Endometrial cancer and BRCA mutations: a systematic review. J Clin Med. 2022;11(11):3114. doi: 10.3390/jcm11113114
   PubMed Web of Science ®Google Scholar
• Zhao S, Chen L, Zang Y, et al. Endometrial cancer in lynch syndrome. Int J Cancer. 2022;150(1):7–17.
   PubMed Web of Science ®Google Scholar
• Brinton LA, Berman ML, Mortel R, et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol. 1992;167(5):1317–1325.
   PubMed Web of Science ®Google Scholar
• Henley SJ, Miller JW, Dowling NF, et al. Uterine cancer incidence and mortality — United States, 1999–2016. MMWR Morb Mortal Wkly Rep. 2018;67(48):1333–1338. doi: 10.15585/mmwr.mm6748a1
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA. 2002;288:321–333. doi: 10.1001/jama.288.3.321
   PubMed Web of Science ®Google Scholar
• Wachtel MM, Yang S, Dissanaike S, et al. Hormone replacement therapy, likely neither angel nor demon. PLoS One. 2015;10:e0138556. doi:10.1371/journal.pone.0138556
   PubMed Web of Science ®Google Scholar
• Steele CB, Thomas CC, Henley SJ, et al. Vital signs: trends in incidence of cancers associated with overweight and obesity—United States, 2005–2014. Morb Mortal Wkly Rep. 2017;66:1052–1058. doi: 10.15585/mmwr.mm6639e1
   PubMed Web of Science ®Google Scholar
• Renehan AG, Tyson M, Egger M, et al. Body mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–578. doi: 10.1016/S0140-6736(08)60269-X
   PubMed Web of Science ®Google Scholar
• Esposito G, Turati F, Serraino D, et al. World cancer research fund/American institute for cancer research recommendations and endometrial cancer risk: a multicentric case-control study. Br J Nutr. 2022;129:1–9. doi: 10.1017/S0007114522002872
   PubMed Web of Science ®Google Scholar
• EE C, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–1638.
   PubMed Web of Science ®Google Scholar
• Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer. 2015;15(8):484–98. doi: 10.1038/nrc3967
   PubMed Web of Science ®Google Scholar
• Park J, Morley TS, Kim M, et al. Obesity and cancer: mechanisms underlying tumor progression and recurrence. Nat Rev Endocrinol. 2014;10:455–465. doi: 10.1038/nrendo.2014.94
   PubMed Web of Science ®Google Scholar
• Cavalieri E, Rogan E. The molecular etiology and prevention of estrogen-initiated cancers: Ockham’s razor: pluralitas non est ponenda sine necessitate. Plurality should not be posited without necessity. Mol Aspects Med. 2014;36:1–55. doi:10.1016/j.mam.2013.08.002
   PubMed Web of Science ®Google Scholar
• Nead KT, Sharp SJ, Thompson DJ, et al. Evidence of a causal association between insulinemia and endometrial cancer: a mendelian randomization analysis. J Natl Cancer Inst. 2015;107:djv178. doi: 10.1093/jnci/djv178
   PubMedGoogle Scholar
• McCampbell AS, Broaddus RR, Loose DS, et al. Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin Cancer Res. 2006;12:6373–6378. doi: 10.1158/1078-0432.CCR-06-0912
   PubMed Web of Science ®Google Scholar
• Aune D, Sen A, Vatten LJ, et al. Hypertension and the risk of endometrial cancer: a systematic review and meta-analysis of case control and cohort studies. Sci Rep. 2017;7:44808. doi: 10.1038/srep44808
   PubMedGoogle Scholar
• Trabert B, Wentzensen N, Felix AS, et al. Metabolic syndrome and risk of endometrial cancer in the United States: a study in the SEER-Medicare linked database. Cancer Epidemiol Biomarkers Prev. 2015;24:261–267. doi: 10.1158/1055-9965.EPI-14-0923
   PubMed Web of Science ®Google Scholar
• Wilczyński M, Danielska J, Wilczyński J. An update of the classical Bokhman’s dualistic model of endometrial cancer. Prz Menopauzalny. 2016;15:63–68. doi: 10.5114/pm.2016.61186
   PubMedGoogle Scholar
• Cancer Genome Atlas Research Network, Kandoth C, Schultz N. et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73. doi: 10.1038/nature12113
   PubMed Web of Science ®Google Scholar
• Stelloo E, Bosse T, Nout RA, et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol. 2015;28:836–844. doi: 10.1038/modpathol.2015.43
   PubMed Web of Science ®Google Scholar
• Talhouk A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015;113(2):299–310. doi: 10.1038/bjc.2015.190
   PubMed Web of Science ®Google Scholar
• Yang Z, Yang X, Liu X, et al. Clinical characteristics and prognostic characterization of endometrial carcinoma: a comparative analysis of molecular typing protocols. BMC Cancer. 2023;23(1):243. doi: 10.1186/s12885-023-10706-8
   PubMed Web of Science ®Google Scholar
• Talhouk A, McConechy MK, Leung S, et al. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017;123:802–813. doi: 10.1002/cncr.30496
   PubMed Web of Science ®Google Scholar
• Abu-Rustum NR, Yashar CM, Bradley K, et al. NCCN Guidelines® insights: uterine neoplasms, version 3.2021. J Natl Compr Canc Netw. 2021;19:888–895. doi: 10.6004/jnccn.2021.0038
   PubMed Web of Science ®Google Scholar
• Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31(1):12–39. doi: 10.1136/ijgc-2020-002230
   PubMed Web of Science ®Google Scholar
• Stelloo E, Nout RA, Osse EM, et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts. Clin Cancer Res. 2016;22(16):4215–4224. doi: 10.1158/1078-0432.CCR-15-2878
   PubMed Web of Science ®Google Scholar
• León-Castillo A, de Boer SM, Powell ME, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy. J Clin Oncol. 2020;38(29):3388–3397. doi: 10.1200/JCO.20.00549
   PubMed Web of Science ®Google Scholar
• de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019;20(9):1273–1285. doi: 10.1016/S1470-2045(19)30395-X
   PubMed Web of Science ®Google Scholar
• Bosse T, Nout RA, McAlpine JN, et al. Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups. Am J Surg Patho. 2018;42(5):561–568. doi: 10.1097/PAS.0000000000001020
   PubMed Web of Science ®Google Scholar
• Stasenko M, Tunnage I, Ashley CW, et al. Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer. Gynecol Oncol. 2020;156(1):194–202. doi: 10.1016/j.ygyno.2019.10.028
   PubMed Web of Science ®Google Scholar
• McAlpine JN, Chiu DS, Nout RA, et al. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: an individual patient data meta-analysis. Cancer. 2021;127(14):2409–2422. doi: 10.1002/cncr.33516
   PubMed Web of Science ®Google Scholar
• Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program. Int J Gynecol Cancer. 2022;33(1):109–117. doi: 10.1136/ijgc-2022-004039
   PubMed Web of Science ®Google Scholar
• Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73. doi: 10.1038/nature12113
   PubMed Web of Science ®Google Scholar
• Talhouk A, McConechy MK, Leung S, et al. Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017;123(5):802–813. doi: 10.1002/cncr.30496
   PubMed Web of Science ®Google Scholar
• Kommoss S, McConechy MK, Kommoss F. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 2018;29(5):1180–1188. doi:10.1093/annonc/mdy058
   PubMed Web of Science ®Google Scholar
• Santoro A, Angelico G, Inzani F, et al. Pathological features, immunoprofile and mismatch repair protein expression status in uterine endometrioid carcinoma: focus on MELF pattern of myoinvasion. Eur J Surg Oncol. 2021;47(2):338–345. doi: 10.1016/j.ejso.2020.06.041
   PubMed Web of Science ®Google Scholar
• Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10. doi: 10.1200/JCO.19.02105
   PubMed Web of Science ®Google Scholar
• Capasso I, Santoro A, Lucci Cordisco E, et al. Lynch syndrome and gynecologic tumors: incidence, prophylaxis, and management of patients with cancer. Cancers (Basel). 2023;15(5):1400.
   PubMed Web of Science ®Google Scholar
• Post CCB, Stelloo E, Smit V, et al. Prevalence and prognosis of lynch syndrome and sporadic mismatch repair deficiency in endometrial cancer. J Natl Cancer Inst. 2021;113(9):1212–1220. doi: 10.1093/jnci/djab029
   PubMedGoogle Scholar
• Kaneko E, Sato N, Sugawara T, et al. MLH1 promoter hypermethylation predicts poorer prognosis in mismatch repair deficiency endometrial carcinomas. J Gynecol Oncol. 2021;32(6):e79. doi: 10.3802/jgo.2021.32.e79
   PubMed Web of Science ®Google Scholar
• Salem ME, Bodor JN, Puccini A, et al. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors. Int J Cancer. 2020;147(10):2948–2956. doi: 10.1002/ijc.33115
   PubMed Web of Science ®Google Scholar
• Stelloo E, Bosse T, Nout RA, et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol. 2015;28(6):836–844. doi: 10.1038/modpathol.2015.43
   PubMed Web of Science ®Google Scholar
• Momeni-Boroujeni A, Nguyen B, Vanderbilt CM, et al. Genomic landscape of endometrial carcinomas of no specific molecular profile. Mod Pathol. 2022;35(9):1269–1278. doi: 10.1038/s41379-022-01066-y
   PubMed Web of Science ®Google Scholar
• Jamieson A, Huvila J, Chiu D, et al. Grade and estrogen receptor expression identify a subset of no specific molecular profile endometrial carcinomas at a very low risk of disease-specific death. Mod Pathol. 2023;36(4):100085. doi: 10.1016/j.modpat.2022.100085
   PubMed Web of Science ®Google Scholar
• Vermij L, Jobsen JJ, León-Castillo A, et al. Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry. Br J Cancer. 2023;128(7):1360–1368. doi: 10.1038/s41416-023-02141-0
   PubMed Web of Science ®Google Scholar
• Amant F, Mirza MR, Koskas M, et al. Cancer of the corpus uteri. Int J Gynaecol Obstet. 2018;143(Suppl 2):37–50. doi:10.1002/ijgo.12612
   PubMed Web of Science ®Google Scholar
• Huijgens AN, Mertens HJ. Factors predicting recurrent endometrial cancer. Facts Views Vis ObGyn. 2013;5(3):179–186.
   PubMedGoogle Scholar
• Kurra V, Krajewski KM, Jagannathan J, et al. Typical and atypical metastatic sites of recurrent endometrial carcinoma. Cancer Imaging. 2013;13(1):113–122. doi: 10.1102/1470-7330.2013.0011
   PubMed Web of Science ®Google Scholar
• Sohaib SA, Houghton SL, Meroni R, et al. Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis. Clin Radiol. 2007;62(1):28–34. discussion 5–6. doi: 10.1016/j.crad.2006.06.015
   PubMed Web of Science ®Google Scholar
• Schwandt A, Chen WC, Martra F, et al. Chemotherapy plus radiation in advanced-stage endometrial cancer. Int J Gynecol Cancer. 2011;21(9):1622–1627. doi: 10.1097/IGC.0b013e31822b6594
   PubMed Web of Science ®Google Scholar
• Ling DC, Vargo JA, Glaser SM, et al. Outcomes after definitive re-irradiation with 3D brachytherapy with or without external beam radiation therapy for vaginal recurrence of endometrial cancer. Gynecol Oncol. 2019;152(3):581–586. doi: 10.1016/j.ygyno.2018.12.022
   PubMed Web of Science ®Google Scholar
• Mabuchi S, Takahashi R, Isohashi F, et al. Reirradiation using high-dose-rate interstitial brachytherapy for locally recurrent cervical cancer: a single institutional experience. Int J Gynecol Cancer. 2014;24(1):141–148. doi: 10.1097/IGC.0000000000000028
   PubMed Web of Science ®Google Scholar
• Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209). J Clin Oncol. 2020;38(33):3841–3850. doi: 10.1200/JCO.20.01076
   PubMed Web of Science ®Google Scholar
• Ott PA, Bang YJ, Berton-Rigaud D, et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study. J Clin Oncol. 2017;35(22):2535–2541. doi: 10.1200/JCO.2017.72.5952
   PubMed Web of Science ®Google Scholar
• Oaknin A, Tinker AV, Gilbert L, et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol. 2020;6(11):1766–1772. doi: 10.1001/jamaoncol.2020.4515
   PubMed Web of Science ®Google Scholar
• Konstantinopoulos PA, Luo W, Liu JF, et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. J Clin Oncol. 2019;37(30):2786–2794. doi: 10.1200/JCO.19.01021
   PubMed Web of Science ®Google Scholar
• Antill Y, Kok PS, Robledo K, et al. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. J Immunother Cancer. 2021;9(6):e002255. doi: 10.1136/jitc-2020-002255
   PubMed Web of Science ®Google Scholar
• Marcus L, Fashoyin-Aje LA, Donoghue M, et al. FDA Approval Summary: Pembrolizumab for the treatment of tumor mutational burden-high solid tumors. Clin Cancer Res. 2021;27(17):4685–4689.
   PubMed Web of Science ®Google Scholar
• Makker V, Colombo N, Casado Herráez A, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386(5):437–448. doi: 10.1056/NEJMoa2108330
   PubMed Web of Science ®Google Scholar
• Makker V, Taylor MH, Aghajanian C, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol. 2020;38(26):2981–2992. doi: 10.1200/JCO.19.02627
   PubMed Web of Science ®Google Scholar
• Oaknin A, Gilbert L, Tinker AV, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study. J Immunother Cancer. 2022;10(1):e003777. doi: 10.1136/jitc-2021-003777
   PubMed Web of Science ®Google Scholar
• EMA. Jemperli. European Medicines Agency. 2021 [cited 2024 Jan 20]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/jemperli
   Google Scholar
• FDA D.I.S.C.O. Burst edition: FDA approvals of Jemperli (dostarlimab-gxly) for patients with mismatch repair deficient recurrent or advanced solid tumors, and opdivo (nivolumab) for the adjuvant treatment of patients with urothelial carcinoma. FDA. 2021 [cited 2024 Jan 20]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approvals-jemperli-dostarlimab-gxly-patients-mismatch-repair-deficient
   Google Scholar
• Walker JL, Piedmonte MR, Spirtos NM, et al. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: gynecologic oncology group LAP2 study. J Clin Oncol. 2012;30:695–700. doi: 10.1200/JCO.2011.38.8645
   PubMed Web of Science ®Google Scholar
• Walker JL, Piedmonte MR, Spirtos NM, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: gynecologic oncology group study LAP2. J Clin Oncol. 2009;27:5331–5336. doi: 10.1200/JCO.2009.22.3248
   PubMed Web of Science ®Google Scholar
• Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73. doi: 10.1038/nature12113
   PubMed Web of Science ®Google Scholar
• Dai Y, Wang J, Zhao L, et al. Tumor molecular features predict endometrial cancer patients’ survival after open or minimally invasive surgeries. Front Oncol. 2021;11:634857. doi: 10.3389/fonc.2021.634857
   PubMed Web of Science ®Google Scholar
• Zhao H, Thienpont B, Yesilyurt BT, et al. Mismatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double-strand breaks. Elife. 2014;3:e02725. doi: 10.7554/eLife.02725
   PubMed Web of Science ®Google Scholar
• Temko D, Van Gool IC, Rayner E, et al. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. J Pathol. 2018;245:283–296. doi: 10.1002/path.5081
   PubMed Web of Science ®Google Scholar
• Dudley JC, Lin MT, Le DT, et al. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res. 2016;22:813–820. doi: 10.1158/1078-0432.CCR-15-1678
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang J, Dai Y, et al. Survival of microsatellite-stable endometrioid endometrial cancer patients after minimally invasive surgery: An analysis of the Cancer Genome Atlas data. Gynecol Oncol. 2020;158:92–98. doi: 10.1016/j.ygyno.2020.04.684
   PubMed Web of Science ®Google Scholar
• Bellone S, Centritto F, Black J, et al. Polymerase ∈ (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients. Gynecol Oncol. 2015;138:11–17. doi: 10.1016/j.ygyno.2015.04.027
   PubMed Web of Science ®Google Scholar
• Fan Y, Ying H, Wu X, et al. The mutational pattern of homologous recombination (HR)-associated genes and its relevance to the immunotherapeutic response in gastric cancer. Cancer Biol Med. 2020;17:1002–1013. doi: 10.20892/j.issn.2095-3941.2020.0089
   PubMed Web of Science ®Google Scholar
• Rajkumar S, Nath R, Lane G, et al. Advanced stage (IIIC/IV) endometrial cancer: role of cytoreduction and determinants of survival. Eur J Obstet Gynecol Reprod Biol. 2019;234:26–31. doi: 10.1016/j.ejogrb.2018.11.029
   PubMed Web of Science ®Google Scholar
• Rauh L, Staples JN, Duska LR, et al. Chemotherapy alone may have equivalent survival as compared to suboptimal surgery in advanced endometrial cancer patients. Gynecol Oncol Rep. 2020;32:100535. doi: 10.1016/j.gore.2020.100535
   PubMed Web of Science ®Google Scholar
• Cianci S, Capozzi VA, Rosati A, et al. Different surgical approaches for early-stage ovarian cancer staging. A large monocentric experience. Front Med. 2022;9:880681. doi: 10.3389/fmed.2022.880681
   Web of Science ®Google Scholar
• Jochum F, Aubry G, Pellerin M, et al. Relevance of laparoscopic surgery for ovarian cancer in well-selected patients: a propensity-matched comparison with laparotomy. Anticancer Res. 2021;41:955–965. doi: 10.21873/anticanres.14849
   PubMed Web of Science ®Google Scholar
• Gueli Alletti S, Capozzi VA, Rosati A, et al. Laparoscopy vs. laparotomy for advanced ovarian cancer: a systematic review of the literature. Minerva Med. 2019;110:341–357. doi: 10.23736/S0026-4806.19.06132-9
   PubMed Web of Science ®Google Scholar
• s G, Zammarrelli WA, Rios-Doria EV, et al. Current evidence-based systemic therapy for advanced and recurrent endometrial cancer. J Natl Compr Canc Netw. 2023;21:217–226. doi: 10.6004/jnccn.2022.7254
   PubMed Web of Science ®Google Scholar
• Jooya ND, Ciccone MA, Brunette LL, et al. Population-level uptake of neoadjuvant chemotherapy for stage IVB endometrial cancer. Gynecol Oncol. 2022;165:428–436. doi: 10.1016/j.ygyno.2022.03.021
   PubMed Web of Science ®Google Scholar
• Kasius JC, Trozzi R, Pijnenborg J, et al. Important endometrial cancer assessment by combining the new technique of genomic profiling with surgical extra uterine disease assessment (EUGINIE). Int J Gynecol Cancer. 2023;33:823–826. doi: 10.1136/ijgc-2023-004289
   PubMed Web of Science ®Google Scholar
• Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333–339. doi: 10.1038/nature12634
   PubMed Web of Science ®Google Scholar
• Marquard AM, Eklund AC, Joshi T, et al. Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark Res. 2015;3(9). doi: 10.1186/s40364-015-0033-4
   PubMedGoogle Scholar
• de Jonge MM, Auguste A, van Wijk LM, et al. Frequent homologous recombination deficiency in high-grade endometrial carcinomas. Clin Cancer Res. 2019;25(3):1087–1097. doi: 10.1158/1078-0432.CCR-18-1443
   PubMed Web of Science ®Google Scholar
• The effect of adjuvant tislelizumab plus chemotherapy on failure free survival after post-operative pelvic chemoradiation in high risk endometrial cancer - ADELE: a randomised phase 2 trial. 2021 [cited 2024 Jan 21] Available from: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380794&isReview=true
   Google Scholar
• ENGOT-en11/GOG-3053/KEYNOTE-B21: phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with newly diagnosed high-risk endometrial cancer. J Clin Oncol. 2021 [cited 2024 Jan 20]; https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.TPS5608.
   Google Scholar
• van den Heerik A, Horeweg N, Nout RA, et al. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. Int J Gynecol Cancer. 2020;30(12):2002–2007. doi: 10.1136/ijgc-2020-001929
   PubMed Web of Science ®Google Scholar
• DUO-E/GOG-3041/ENGOT-EN10: a randomized phase III trial of first-line carboplatin (carb) and paclitaxel (pac) in combination with durvalumab (durva), followed by maintenance durva with or without olaparib (ola), in patients (pts) with newly diagnosed (nd) advanced or recurrent endometrial cancer (EC). 2020 [cited 2024 Jan 20]. Available from: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.TPS6108
   Google Scholar
• Imfinzi plus Lynparza and Imfinzi alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy [Press Release]. 2023 [cited 2024 Jan 20]. Available from: https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-plus-lynparza-reduced-risk-disease-progression-death-45-percent-vs-chemotherapy-advanced-recurrent-endometrial-cancer.html
   Google Scholar
• University of Colorado D. A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer. 2021 [cited 2024 Jan 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03617679.
   Google Scholar
• Bradley WH, Hayes MP, Taylor N, et al. Non-randomized multisite phase II trial combining bevacizumab, atezolizumab and rucaparib for the treatment of previously treated recurrent and progressive endometrial carcinoma. J Clin Oncol. 2022;40(16_suppl):5510. doi: 10.1200/JCO.2022.40.16_suppl.5510
   Web of Science ®Google Scholar
• A phase 2 multicenter, open-label study of rucaparib as treatment for solid tumors associated with deleterious mutations in homologous recombination repair genes. clinicaltrials.Gov. 2021 [cited 2024 Jan 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT04171700
   Google Scholar
• AstraZeneca. A randomised, multicentre, double-blind, placebo-controlled, phase III study of first-line carboplatin and paclitaxel in combination with durvalumab, followed by maintenance durvalumab with or without olaparib in patients with newly diagnosed advanced or recurrent endometrial cancer (DUO-E) clinicaltrials.Gov 2022 [cited 2024 Jan 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT04269200
   Google Scholar
• Post CCB, Westermann AM, Boere IA, et al. Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial). Gynecol Oncol. 2022;165(2):223–229. doi: 10.1016/j.ygyno.2022.02.025
   PubMed Web of Science ®Google Scholar
• You B A phase I/II trial to assess the safety and efficacy of metronomic cyclophosphamide, metformin and olaparib in recurrent advanced/metastatic endometrial cancer patients. Clinicaltrials.Gov. 2021. [cited 2024 Jan 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT02755844.
   Google Scholar
• Joly F, ARCAGY/GINECO GROUP. Multicenter double blind randomized phase II trial of olaparib vs placebo as maintenance therapy in platinum-sensitive advanced endometrial carcinoma [Internet]. clinicaltrials.gov. 2021 [cited 2024 Jan 21]. Available from: http://clinicaltrials.gov/ct2/show/NCT03745950
   Google Scholar
• Jaison G, The Christie NHS Foundation Trust. A 3-arm randomised phase II evaluation of cediranib in combination with weekly paclitaxel or olaparib versus weekly paclitaxel chemotherapy for advanced endometrial carcinoma or for disease relapse within 18 months of adjuvant carboplatin-paclitaxel chemotherapy. clinicaltrials.gov. 2019 [cited 2024 Jan 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT03745950
   Google Scholar
• Mackay HJ, Oncology NRG. A randomized phase II study comparing single-agent olaparib, single agent cediranib, and the combinations of cediranib/olaparib, olaparib/Durvalumab (MEDI4736), cediranib/Durvalumab (MEDI4736), olaparib/AZD5363 (capivasertib) in women with recurrent, persistent or Metastatic Endometrial cancer. A multi-arm trial for women with recurrent or persistent Endometrial cancer clinicaltrials.Gov. 2022 [cited 2024 Jan 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT03660826
   Google Scholar
• Banerjee S, Royal Marsden NHS Foundation Trust. ATARI: aTr inhibitor in combination with olaparib in gynaecological cancers with ARId1A loss. Clinicaltrials.Gov. 2020 [cited 2024 Jan 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT04065269
   Google Scholar
• Westin SN, M.D. Anderson Cancer Center. A phase Ib study of the oral PARP inhibitor olaparib with the oral mTORC1/2 inhibitor AZD2014 or the oral AKT inhibitor AZD5363 for recurrent endometrial, triple negative breast, and ovarian, primary peritoneal, or fallopian tube cancer. clinicaltrials.gov. 2020 [cited 2024 Jan 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT02208375
   Google Scholar
• Oza AM, UHN - Princess Margaret Cancer Centre. A phase II, open label study of the Poly(ADP-ribose) polymerase inhibitor niraparib in mono therapy or in combination with anti-PD1 inhibitor TSR-042 in recurrent endometrial cancer. clinicaltrials.gov. 2021 [cited 2024 Jan 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT03016338
   Google Scholar
• Jundong L, Sun Yat-sen University. Phase II trial of niraparib in combination with anti-PD1 antibody in recurrent/advanced stage endometrial cancer patients. clinicaltrials.Gov. 2021 [cited 2024 Jan 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT04885413.
   Google Scholar
• Sun Yat-sen University, Tongji Hospital, Women’s Hospital School Of Medicine Zhejiang University, et al. Niraparib monotherapy as maintain and recurrent treatment of endometrial serous carcinoma: a multi-center, open-label, prospective clinical study. Clinicaltrials.Gov. 2021 [cited 2024 Jan 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT04716686.
   Google Scholar
• Frimer M, Northwell Health. Trial of maintenance with niraparib in patients with stage III, stage IV or platinum-sensitive recurrent uterine serous carcinoma. clinicaltrials.Gov. 2021 [cited 2024 Jan 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT04080284
   Google Scholar
• ARCAGY/GINECO GROUP. A multicentric randomized phase II/III evaluating TSR-042 (anti-PD-1 mAb) in combination with niraparib (parpi) versus niraparib alone compared to chemotherapy in the treatment of metastatic or recurrent endometrial or ovarian carcinosarcoma after at least one line of chemotherapy. Clinicaltrials.Gov. 2021 [cited 2024 Jan 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT03651206.
   Google Scholar
• Fader AN, Roque DM, Siegel E, et al. Randomized Phase II Trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu. J Clin Oncol. 2018 [cited 2024 Jan 21];36(20):2044–2051. doi: 10.1200/JCO.2017.76.5966
   PubMed Web of Science ®Google Scholar
• Ali-Ahmad HM, Rothe M, Mangat PK, et al. Pertuzumab plus trastuzumab (P+T) in patients (pts) with uterine cancer (UC) with ERBB2 or ERBB3 amplification, overexpression or mutation: results from the targeted agent and profiling utilization registry (TAPUR) study. J Clin Oncol. 2021 [cited 2024 Jan 21];39(15 Suppl):5508–5508. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.5508
   Web of Science ®Google Scholar
• AstraZeneca. A phase II, multicenter, open-label study to evaluate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) for the treatment of unresectable and/or metastatic solid tumors harboring HER2 activating mutations regardless of tumor histology. 2022 [cited 2024 Jan 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT04639219
   Google Scholar
• Maio M, Ascierto PA, Manzyuk L, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. 2022;33(9):929–938. doi: 10.1016/j.annonc.2022.05.519
   PubMed Web of Science ®Google Scholar
• Sharp M, Dohme LLC, ENGOT, GOG Foundation. A phase 3 randomized, open-label, active-comparator controlled clinical study of pembrolizumab versus platinum doublet chemotherapy in participants with mismatch repair deficient (dMMR) advanced or recurrent endometrial carcinoma in the first-line setting (KEYNOTE-C93/GOG-3064/ENGOTen15). clinicaltrials.Gov. (2021) [cited 2024 Jan 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT05173987
   Google Scholar
• Merck’s KEYTRUDA® plus chemotherapy met primary endpoint of progression-free survival as first-line therapy for advanced or recurrent endometrial carcinoma [Press Release]. 2023. https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-met-primary-endpoint-of-progression-free-survival-pfs-as-first-line-therapy-for-advanced-or-recurrent-endometrial-carcinoma/
   Google Scholar
• Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med. 2023;388(23):2159–70. doi: 10.1056/NEJMoa2302312
   PubMed Web of Science ®Google Scholar
• Joly F, ARCAGY/GINECO GROUP. Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus dostarlimab in first line Advanced/Metastatic setting. clinicaltrials.Gov. 2022 [cited 2024 Jan 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT05201547
   Google Scholar
• Tinker AV, Sabatier R, Gravina A, et al. 2022-RA-1198-ESGO Post hoc analysis of objective response rate by mismatch repair protein dimer loss/mutation status in patients with mismatch repair deficient endometrial cancer treated with dostarlimab. Intl J Gynecol Cancer. 2022;32:A414.
   PubMed Web of Science ®Google Scholar
• Mirza MR, Coleman RL, Hanker LC, et al. ENGOT-EN6/NSGO-RUBY: a phase III, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC). clinicaltrials.Gov. J Clin Oncol. 2020;38(15_suppl):TPS6107. doi: 10.1200/JCO.2020.38.15_suppl.TPS6107
   Web of Science ®Google Scholar
• Mirza MR, Chase DM, Slomovitz BM, et al. Dostarlimab for primary advanced or recurrent endometrial cancer. N Engl J Med. 2023;388(23):2145–2158. doi: 10.1056/NEJMoa2216334
   PubMed Web of Science ®Google Scholar
• Jemperli (dostarlimab) RUBY phase III trial met its primary endpoint in a planned interim analysis in patients with primary advanced or recurrent endometrial cancer [ press release]. 2022 [cited 2024 Jan 21]. Available from: https://www.gsk.com/en-gb/media/press-releases/jemperli-dostarlimab-ruby-phase-iii-trial-met-its-primary-endpoint-in-a-planned-interim-analysis-in-patients-with-primary-advanced-or-recurrent-endometrial-cancer/
   Google Scholar
• National Cancer Institute. MITO END-3: a randomized phase II trial of carboplatin+paclitaxel compared to carboplatin+paclitaxel +avelumab in advanced (Stage III-IV) or recurrent endometrial cancer Clinicaltrials.gov. 2021 [cited 2024 Jan 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT03503786
   Google Scholar
• Colombo N, Antill Y, Barretina Ginesta MF, et al. AtTEnd/ENGOTen7: a multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer. Ann Oncol Abstract. 2020;31:S647. doi: 10.1016/j.annonc.2020.08.2090
   Web of Science ®Google Scholar
• Eskander RN, Oncology NRG. A phase III randomized, placebo-controlled study of pembrolizumab (MK-3475, NSC #776864) in addition to paclitaxel and carboplatin for measurable stage III or IVA, stage IVB or recurrent endometrial cancer 2021 [cited 2024 Jan 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT03914612.
   Google Scholar
• Rižner TL. Discovery of biomarkers for endometrial cancer: Current status and prospects. Expert Rev Mol Diagn. 2016;16:1315–1336. doi:10.1080/14737159.2016.1258302
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia E, Lopez-Gil C, Campoy I, et al. Advances in endometrial cancer protein biomarkers for use in the clinic. Expert Rev Proteom. 2018;15:81–99. doi: 10.1080/14789450.2018.1410061
   PubMed Web of Science ®Google Scholar
• González-Rodilla I, Aller L, Llorca J, et al. The E-cadherin expression vs. tumor cell proliferation paradox in endometrial cancer. Anticancer Res. 2013;33:5091–5096.
   PubMed Web of Science ®Google Scholar
• Wang Y, Han C, Teng F, et al. Predictive value of serum HE4 and CA125 concentrations for lymphatic metastasis of endometrial cancer. Int J Gynecol Obst. 2016;136:58–63. doi: 10.1002/ijgo.12010
   PubMed Web of Science ®Google Scholar
• Zanotti L, Bignotti E, Calza S, et al. Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome. Clin Chem Lab Med. 2012;50:2189–2198. doi: 10.1515/cclm-2011-0757
   PubMed Web of Science ®Google Scholar
• Chao A, Tang YH, Lai CH, et al. Potential of an age-stratified CA125 cut-off value to improve the prognostic classification of patients with endometrial cancer. Gynecol Oncol. 2013;129:500–504. doi: 10.1016/j.ygyno.2013.02.032
   PubMed Web of Science ®Google Scholar
• Stiekema A, Lok C, Korse C, et al. Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer. Virchows Arch. 2017;470(6):655–664. doi: 10.1007/s00428-017-2115-1
   PubMed Web of Science ®Google Scholar